311 related articles for article (PubMed ID: 36566258)
41. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma.
Lopez-Ramirez F; Sardi A; Studeman K; King MC; Falla-Zuniga LF; Nikiforchin A; Baron E; Nieroda C; Gushchin V; Diaz-Montes T
Eur J Surg Oncol; 2023 Aug; 49(8):1495-1503. PubMed ID: 37068984
[TBL] [Abstract][Full Text] [Related]
42. Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis.
Chidambarasamy ES; Chia CS; Johnny Ong CA; Soo KC; Ching Teo MC; Ching Tan GH
Asian J Surg; 2022 Jan; 45(1):339-345. PubMed ID: 34148748
[TBL] [Abstract][Full Text] [Related]
43. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
44. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
45. A total neoadjuvant chemotherapy approach is associated with improved recurrence-free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and HIPEC.
Hanna DN; Macfie R; Ghani MO; Hermina A; Mina A; Cha DE; Bailey CE; Cohen N; Labow D; Golas B; Sarpel U; Magge D; Idrees K
J Surg Oncol; 2023 Mar; 127(3):442-449. PubMed ID: 36350108
[TBL] [Abstract][Full Text] [Related]
46. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
[TBL] [Abstract][Full Text] [Related]
47. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer.
Piso P; Stierstorfer K; Gerken M; Klinkhammer-Schalke M
Int J Colorectal Dis; 2018 Nov; 33(11):1559-1567. PubMed ID: 30132068
[TBL] [Abstract][Full Text] [Related]
48. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
[TBL] [Abstract][Full Text] [Related]
49. Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials.
Green BL; Blumenthaler AN; Gamble LA; McDonald JD; Robinson K; Connolly M; Epstein M; Hernandez JM; Blakely AM; Badgwell BD; Davis JL
Ann Surg Oncol; 2023 Mar; 30(3):1852-1860. PubMed ID: 36348206
[TBL] [Abstract][Full Text] [Related]
50. Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients.
Yan G; Zhang K; Yan L; Zhang Y
World J Surg Oncol; 2024 May; 22(1):144. PubMed ID: 38822337
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant Chemotherapy Followed by Cytoreductive Surgery and HIPEC Improves Survival in Peritoneal Metastatic Gastric Cancer.
Akturk Esen S; Ozgun YM; Hasturk D; Ucar G; Bostanci EB; Sendur MAN; Uncu D
Oncology; 2023; 101(5):321-327. PubMed ID: 36809752
[TBL] [Abstract][Full Text] [Related]
52. The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Dietz MV; van Kooten JP; van Vugt JLA; Brandt-Kerkhof ARM; Verhoef C; Madsen EVE
Ann Surg Oncol; 2022 Sep; 29(9):5830-5841. PubMed ID: 35650370
[TBL] [Abstract][Full Text] [Related]
53. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis.
Repullo DJ; Barbois S; Leonard D; Bohlok A; Van den Audenaeren ET; Hendlisz A; Van den Eynde M; Donckier V; Kartheuser A; Liberale G
Eur J Surg Oncol; 2021 Jul; 47(7):1661-1667. PubMed ID: 33602530
[TBL] [Abstract][Full Text] [Related]
54. Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Devilee RA; Simkens GA; van Oudheusden TR; Rutten HJ; Creemers GJ; Ten Tije AJ; de Hingh IH
Ann Surg Oncol; 2016 Sep; 23(9):2841-8. PubMed ID: 27044447
[TBL] [Abstract][Full Text] [Related]
55. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
[TBL] [Abstract][Full Text] [Related]
56. Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative.
Fackche NT; Schmocker RK; Nudotor R; Kubi B; Cloyd JM; Grotz TE; Fournier KF; Dineen SP; Veerapong J; Baumgartner JM; Clarke CN; Patel SH; Wilson GC; Lambert LA; Pokrzywa C; Abbott DE; Lee B; Staley CA; Zaidi MY; Johnston FM; Greer JB
Ann Surg Oncol; 2024 May; 31(5):3314-3324. PubMed ID: 38310181
[TBL] [Abstract][Full Text] [Related]
57. Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study.
van der Ven RGFM; van den Heuvel TBM; Rovers KPB; Nienhuijs SW; Boerma D; van Grevenstein WMU; Hemmer PHJ; Kok NFM; Madsen EVE; de Reuver P; Tuynman JB; van Erning FN; de Hingh IHJT
Ann Surg Oncol; 2024 Jun; 31(6):3758-3768. PubMed ID: 38453767
[TBL] [Abstract][Full Text] [Related]
58. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study.
Livin M; Leonard D; Bachmann R; Remue C; Barbois S; Cotte E; Van Den Eynde M; De Cuyper A; Sinapi I; Van Maanen A; Kartheuser A
Acta Gastroenterol Belg; 2022; 85(4):573-579. PubMed ID: 36566366
[TBL] [Abstract][Full Text] [Related]
59. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
[TBL] [Abstract][Full Text] [Related]
60. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
